首页/数据集/Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma

Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma

NIAID Data Ecosystem2026-05-01 收录

弥漫性中线胶质瘤

药物联合疗法

数据链接：

https://figshare.com/articles/dataset/Supplementary_Data_from_ONC201_in_Combination_with_Paxalisib_for_the_Treatment_of_H3K27-Altered_Diffuse_Midline_Glioma/23683824 数据链接链接失效反馈

官方服务：

资源简介：

All Supplementary Tables

应用场景：

创建时间：

2023-07-14

肿瘤临床试验

药物联合疗法

This multi-center, open label Phase II clinical study is performed in patients with unresectable or metastatic malignant tumors of the digestive system (colorectal cancer, gastric cancer). This study

NIAID Data Ecosystem60

Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer

转移性结直肠癌治疗

药物联合疗法

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in d

NIAID Data Ecosystem30

Additional file 1 of Co-prescribing of antidepressants and opioids for non-cancer pain in England, 2010–2019: a descriptive study using CPRD primary care electronic health records

药物联合疗法

药物流行病学

Additional file 1. Code lists for CPRD GOLD used to identify antidepressants, opioids for non-cancer pain, ethnic group, neuropathic pain, depression, anxiety / phobia, cancer, terminal illness, opioi

Figshare2025-08-16 更新20

KCP SHP2i + ERKi

KRAS突变胰腺癌治疗

药物联合疗法

KRAS mutant pancreatic tumors have poor prognosis and few therapeutic options. Here, Frank et al. show that the combination of RMC4550 (SHP2 inhibitor) and LY3214996 (ERK inhibitor) effectively impai

NIAID Data Ecosystem40

Table_1_Clinical Features and Molecular Markers on Diffuse Midline Gliomas With H3K27M Mutations: A 43 Cases Retrospective Cohort Study.docx

弥漫性中线胶质瘤

H3K27M突变分子标志物

PurposeDiffuse midline gliomas (DMG) with H3K27M mutations have been identified as a rare distinctive entity with unique genetic features, varied molecular alterations, and poor prognosis. The current

NIAID Data Ecosystem30

Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma

资源简介：

相关数据集